Direct-to-toxicology viral vector services

Fact Sheet

Toxicology studies are crucial for supporting pre-IND regulatory requirements and evaluating the risk-benefit ratio of drug candidates. However, acquiring high-quality toxicology materials can often stretch timelines, and the incompatibility between toxicology materials generation processes and current good manufacturing practice regulations can impede smooth transitions. Our direct-to-toxicology viral vector services program expedites the route to toxicology materials through our adeno-associated virus (AAV) and lentivirus (LV) production processes, completing them in as little as six months.